COMPETION LEVELS OF ANTIDEPRESSANTS, ANXIOLYTICS AND ANTIPSYCHOTICS SEGMENTS IN THE MARKET OF THE REPUBLIC OF UZBEKISTAN USING THE HERFINDAHL-HIRSCHMAN INDEX

Abror A. Rahimov Assistant, Doctoral research scholar, Tashkent Pharmaceutical Institute, Chair of Organizing Pharmacy, e-mail: iuzpharm@gmail.com https://orcid.org/0000-0003-3563-0427. Aybek St. 45, Mirabad district, Tashkent, Uzbekistan
Dilfuza T. Saipova Candidate of Pharmaceutical Sciences, Associate Professor, Director of the Training and Consulting Center "DIAR-PROFI" LLC e-mail: dilfuza_saipova@rambler.ru Kuk Su St.,47, Almazar district, Tashkent, Uzbekistan.
Bekhzod Abdullaev MD, Research Scholar, Department of Oncology, Akfa University, Email: b.abdullaev@akfauniversity.org 10, 1st Deadlock, Kukcha Darvoza, Tashkent, Uzbekistan.

Abstract

Foreign experience shows that with the increase in the level of competition and the departure from the monopoly in the pharmaceutical sector, the key role is played by the regulators in this area, such as the FDA - the US Food and Drug Administration and EMA - the European Medicines Agency. These regulators, developing various simplified, accelerated registration schemes for generics and reducing information asymmetry (open data of conducted clinical trials by stages and results) indirectly help to reduce "entry barriers" to the market and thereby further increase the availability of certain drugs as price and quality.Accurate and reliable marketing data analysis of the market value in dynamics is the starting point for the development and production of antidepressants, anxiolytics and antipsychotics for the manufacturer, as well as a valuable product for the wholesale and retail segment with its efficient distribution and logistics system. Methods. We studied and analyzed the data on the import and production of antidepressants, anxiolytics and antipsychotics in packages according to the manufacturer's company to determine the dynamics of changes in the competition level in the studied market segments using the Herfindahl-Hirschman index (HHI) in the period from 2006 to 2018. Results. On the basis of retrospective data analysis, it was established that the anxiolytic market in the Republic of Uzbekistan is characterized by oligopoly competition, and monopolistic competition prevails for antidepressants and antipsychotics. Conclusion. The results of the study can be used to further justification of the marketing decisions on the part of both pharmaceutical manufacturers and distributors as well.

Keywords:

antidepressants, anxiolytics, antipsychotics, Herfindahl-Hirschman Index, competition level, oligopoly competition.


Full Text:

PDF


References


1. Karin Fura, Elsa Horn af Rantzien. Master’s thesis in Economics // STOCKHOLM SCHOOL OF ECONOMICS. - 2016-17 2. Chintan V Dave , Aaron S Kesselheim, Erin R Fox, Peihua Qiu, Abraham Hartzema. High Generic Drug Prices and Market Competition: A Retrospective Cohort Study // Ann Intern Med. – 2017. 1; 167(3):145-151. 3. Tarald O.Kvålseth. Relationship between concentration ratio and Herfindahl-Hirschman index: A re-examination based on majorization theory // Helion, V.4 – issue 10. 4. Igor S. Berezin. “Marketing analysis. Market. Firm. Product. Promotion// 3rd Issue, rev. and add. - Moscow: Vershina, - 2008. – P.480. 5. On improving the order of import, export and transit through the territory of the Republic of Uzbekistan of narcotic drugs, psychotropic substances and precursors, as well as control over their circulation // http: //www.lex.uz/docs/2815342 6. Yan Feng, Michele Pistollato, Anita Charlesworth, Nancy Devlin, Carol Propper, Jon Sussex. Association between market concentration of hospitals and patient health gain following hip replacement surgery// J Health Serv Res Policy. - 2015; - 20(1). 11–17. 7. Eric Nauenberg, Mahdi Alkhamisi, Yuri Andrijuk. Simulation of a Hirschman-Herfindahl index without complete market share information// Health Econ. - 2004;13(1):87-94. 8. Yan Tang, Chung-Chou H. Chang, Judith R. Lave, Walid F. Gellad, Haiden A. Huskamp, Julie M. Donohue. Patient, Physician and Organizational Influences on Variation in Antipsychotic Prescribing Behavior// J Ment Health Policy Econ. 9. Hosein Shabaninejad, Hasan Yusefzadeh, Gholamhossein Mehralian, Bahlol Rahimi. The Structure of the World Pharmaceutical Market: Prioritizing Iran’s Target Export Markets// Iran J Pharm Res. – 2019. - 18(1), - P.546–555. 10. Ning Cheng, Tannista Banerjee, Jingjing Qian, Richard A Hansen. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011// J Am Pharm Assoc. - (2003). -2017; -57(3)- P.341-348. 11. Aashna Mehta , Habib Hasan Farooqui, Sakthivel Selvaraj. A Critical Analysis of Concentration and Competition in the Indian Pharmaceutical Market// PLoS One.- 2016. -19;11(2):148951 12. Ravi Gupta, Nilay D Shah, Joseph S Ross. Generic Drugs in the United States: Policies to Address Pricing and Competition// Clin Pharmacol Ther. - 2019 Feb;105(2):329-337. 13. Pieter Dylst, Steven Simoens. Does the market share of generic medicines influence the price level?: a European analysis// Pharmacoeconomics. - 2011 Oct;29(10):875-82. 14. Aaron S Kesselheim, Michael S Sinha, Jerry Avorn. Determinants of Market Exclusivity for Prescription Drugs in the United States// JAMA Intern Med.- 2017 Nov 1;177(11):1658-1664. 15. Aaron S Kesselheim, Jerry Avorn, Ameet Sarpatwari. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform// JAMA. 2016 Aug 23-30;316(8):858-71. 16. Boyang Bian, Elizabeth Gorevski, Christina M L Kelton, Jeff J Guo, Jill E Martin Boone. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam// J Manag Care Pharm. - 2012 Sep;18(7):506-15. 17. Tasaka Y, Tanaka A, Ido K, Tanaka M, Araki H. Estimation of the economic impact associated with pharmaceutical interventions// Jpn J Pharm Health Care Sci. - 2014;40:208–14. 18. Pharmaceuticals and Medical Devices Agency(PMDA). http://www.pmda.go.jp. Accessed 27 Apr 2014. 19. Shikamura Y, Oyama A, Takahashi J, Akagi Y, Negishi K, Ijyuin K, et al. Medical economics research on awareness of community pharmacists about raising pharmaceutical questions regarding prescriptions issued by physicians// Yakugaku Zasshi. - 2012;132(6):753–61.

Refbacks

  • There are currently no refbacks.